Episode
Age-Less Cognition: The Real Science of SEMAX | Age-Less Top 20 Peptides
- Published
- Jun 25, 2026
- Duration seconds
- 1900
- Processing state
not_requested- Canonical source
- https://rss.com/podcasts/the-science-of-age-less-living/2942749
Actions
POST https://stenobird.com/v1/public/podcasts/the-science-of-age-less-living-7235688/episodes/age-less-cognition-the-real-science-of-semax-age-less-top-20-peptides/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-science-of-age-less-living-7235688/age-less-cognition-the-real-science-of-semax-age-less-top-20-peptides.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
SEMAX is one of the most discussed cognitive compounds in the longevity and nootropic world — and arguably one of the most poorly understood. In this episode, Dr. Ethan does what this series always does: follows the science wherever it leads, without the hype and without the dismissiveness. The story of SEMAX starts not in a supplement company's marketing department, but in a Soviet government research institute in the 1980s, where neuropeptide scientists were asking a genuinely interesting question: could fragments of ACTH — the pituitary hormone best known for driving cortisol production — exert direct effects on the brain entirely independent of the adrenal axis? The answer was yes. And SEMAX was the engineered result: a stable, intranasally bioavailable heptapeptide designed to deliver those neuropeptide effects to the central nervous system. The mechanistic story is one of the more coherent in this series. SEMAX upregulates BDNF — brain-derived neurotrophic factor — in hippocampal and prefrontal circuits, the very regions most implicated in age-related cognitive decline. It modulates serotonin availability. It attenuates neuroinflammatory cascades. Each of those mechanisms has a plausible link to cognitive ageing, and together they form a rational basis for the compound's proposed effects. The evidence picture is more complicated. SEMAX has genuine peer-reviewed data — animal studies, Russian clinical trials in stroke and cerebrovascular disease, a 40-year research history. It is a licensed pharmaceutical in Russia, not a grey-market research chemical. But the clinical data has real structural limitations, and for the application most listeners are actually interested in — sharper cognition in a healthy ageing adult — the human randomised controlled trial evidence…